Managers / Q1 2026
BIOS Capital Management, LP
CIK 0001813845 · 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107 · 817-984-9197
Summary
Bios Capital Management, LP reported $53M in U.S.-listed holdings across 10 positions for Q1 2026.
The portfolio is heavily concentrated: ACTU alone accounts for 44.5% of reported value.
The book was largely unchanged from Q4 2025.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $53M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| INABIN8BIO INC | TRIMMED | −85.6K | 167.8K | −$344,645 | $248,351 |
| RNTXREIN THERAPEUTICS INC | ADDED | +291.6K | 1.98M | +$615,817 | $3M |
| LTRNLANTERN PHARMA INC | TRIMMED | −145.1K | 864.4K | −$2M | $1M |
| ACTUACTUATE THERAPEUTICS INC | HELD | +0 | 10.05M | −$34M | $28M |
| IRDOPUS GENETICS INC | HELD | +0 | 3.68M | +$9M | $17M |
| CGTXCOGNITION THERAPEUTICS INC | HELD | +0 | 6.00M | −$4M | $5M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ACTUACTUATE THERAPEUTICS INChistory → | COM | 52.09% | $28M | 10.05M |
| 2 | IRDOPUS GENETICS INChistory → | COM | 31.70% | $17M | 3.68M |
| 3 | CGTXCOGNITION THERAPEUTICS INChistory → | COM | 8.63% | $5M | 6.00M |
| 4 | RNTXREIN THERAPEUTICS INChistory → | COM NEW | 4.87% | $3M | 1.98M |
| 5 | LTRNLANTERN PHARMA INChistory → | COM | 2.24% | $1M | 864.4K |
| 6 | INABIN8BIO INC | COM NEW | 0.47% | $248,351 | 167.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $53M | 10 | May 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $83M | 9 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $89M | 9 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $73M | 9 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $79M | 9 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $94M | 9 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Steelhead Capital Management, LLC028-24869
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.